Search Results
488 results found for "Cost-efficient medications https://simplemedrx.top"
- Anavex to Present on Sigma-1 Receptors at the World Orphan Drug Congress and New Epilepsy Data
(OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Appoints Epilepsy and Clinical Trial Methodology Expert to Scientific Advisory Board
Statements in this press release are not the official view of NYU Langone Medical Center. (OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Appoints Scientific Advisory Board Member; Expert in Protein Misfolding Neurodegenerative Diseases
private funding agencies worldwide, including the US National Institutes of Health (NIH) and the UK Medical (OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Report Fiscal First Quarter 2015 Financial Results
(OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Confirms Positive Preclinical Epilepsy Data for ANAVEX 2-73
The key, however, to the next generation of epilepsy therapies is safety since most currently used epilepsy About Epilepsy Epilepsy is the most common serious neurological disorder, affecting people of all ages (OTCQB: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Doses First Alzheimer's Patient in Phase 2a Trial of ANAVEX 2-73 and ANAVEX PLUS
(OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Announces Fiscal 2014 Fourth Quarter and Year-End Financial Results
(OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Enrollment of Alzheimer's Patients in Phase 2a Clinical Trial of ANAVEX 2-73 and ANAVEX PLUS Begins
Today, Alzheimer’s disease remains the largest unmet medical need in neurology. More than 25 million people are currently diagnosed with Alzheimer’s, with the associated cost of care (OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Upgrades to OTCQX Marketplace
(OTCQX: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex Announces Positive Phase 1 Data for ANAVEX 2-73, Lead Candidate for Treatment of Alzheimer's
investigational compound as a potential treatment option for this devastating disease with high unmet medical About Alzheimer’s Disease Today, Alzheimer’s disease remains the largest unmet medical need in neurology More than 25 million people are currently diagnosed with Alzheimer’s, with the associated cost of care projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex to Present Full Phase 1 Clinical Trial Data for ANAVEX 2-73 at CNS Summit 2014 Conference
(OTCQB: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
- Anavex to Present at SeeThruEquity Investor Conference in New York City
(OTCQB: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel drug projected in any of such statements due to various factors, including the risks set forth in the Company’s most Research & Business Development Toll-free: 1-844-689-3939 Email: info@anavex.com Shareholder & Media
